Medical University of Warsaw, Kondratowicza 8, 03-242 Warszawa, Poland.
Neurol Neurochir Pol. 2021;55(1):97-101. doi: 10.5603/PJNNS.a2020.0097. Epub 2020 Dec 14.
AIM OF THE STUDY: To examine possible features of neuroinflammation in progressive supranuclear palsy - Richardson syndrome and corticobasal syndrome (CBS). CLINICAL RATIONALE FOR THE STUDY: Neutrophil-to-lymphocyte ratio (NLR) is a parameter reflecting inflammation used in numerous branches of medicine. The search for pathogenesis of the diseases partly related to inflammatory processes confirms the need to obtain possible factors which could be relatively easily verified. NLR is a benchmark routinely evaluated in most hospitalised patients. MATERIALS AND METHODS: 23 patients with a clinical diagnosis of PSP-RS, 18 patients with CBS, and 32 healthy controls, were included in the study. Blood samples were assessed in the context of neutrophil and lymphocyte rates. Subsequently, the results were transformed into neutrophil-to-lymphocyte ratio (NLR). The NLRs from each group were statistically assessed using a Kruskal-Wallis test and post-hoc analysis. RESULTS: Statistical analysis confirmed significant differences in NLR between PSP-RS and control group. No other significant differences were observed. CLINICAL IMPLICATIONS: The possible use of NLR in the additional examination of atypical parkinsonisms. CONCLUSIONS: To the best of our knowledge, this is the first study comparing this aspect of neuroinflammation in PSP and CBS. It presents NLR as a promising non-specific parameter in neurodegenerative diseases.
研究目的:探讨进行性核上性麻痹-理查森综合征和皮质基底节综合征(CBS)中神经炎症的可能特征。
研究临床意义:中性粒细胞与淋巴细胞比值(NLR)是一种反映炎症的参数,在许多医学领域都有应用。对部分与炎症过程相关疾病的发病机制的研究证实,需要获得可能的、相对容易验证的因素。NLR 是大多数住院患者常规评估的基准。
材料和方法:本研究纳入了 23 例临床诊断为 PSP-RS 的患者、18 例 CBS 患者和 32 名健康对照者。评估了血液样本中的中性粒细胞和淋巴细胞比率。随后,将结果转化为中性粒细胞与淋巴细胞比值(NLR)。使用 Kruskal-Wallis 检验和事后分析对每组 NLR 进行统计学评估。
结果:统计分析证实了 PSP-RS 组和对照组之间 NLR 的显著差异。未观察到其他显著差异。
临床意义:NLR 可能用于对不典型帕金森病的进一步检查。
结论:据我们所知,这是首次比较 PSP 和 CBS 中神经炎症这一方面的研究。它提出 NLR 是神经退行性疾病中有前途的非特异性参数。
Diagnostics (Basel). 2022-7-9
Neurol Neurochir Pol. 2023
Int J Mol Sci. 2023-10-13
Neuropathol Appl Neurobiol. 2014-2
Front Mol Neurosci. 2024-10-11
Biomedicines. 2024-10-4
IBRO Neurosci Rep. 2024-5-6
J Multidiscip Healthc. 2023-11-8
Int J Mol Sci. 2023-10-13
Front Immunol. 2023